Hengrui Medicine announced that the company and its subsidiaries have recently received the Notice of Drug Clinical Trial Approval issued by the State Food and Drug Administration for the HR18034 injection which will start clinical trials in the near future.
The HR18034 for injection is a long-acting local anesthetic, intended for postoperative analgesia.
At present, similar drugs are being developed overseas and are currently in clinical trials. There is no similar product on the market at home and abroad.
Up to now, the product has been invested a total of about 7.81 million yuan in research and development.